Theravance Biopharma
OverviewSuggest Edit
Theravance Biopharma is a biopharmaceutical company which provides medicines to treat serious illnesses. It focuses on several therapeutic areas, including infectious disease, respiratory, gastrointestinal disease, and cardiovascular and renal disease.
| Type | Public | |
| Founded | 1996 | |
| HQ | Dublin, IE | Map |
| Website | theravance.com | |
| Employee Ratings | More | |
| Overall Culture | B+ | More |
Recent NewsAll News
- Theravance Biopharma to Report Second Quarter 2021 Financial Results on August 3, 2021
- Theravance Biopharma, Inc. Announces Pricing of Public Offering of Ordinary Shares
- Theravance Biopharma, Inc. Announces Top-Line Results From Phase 2 Study of Nezulcitinib In Patients Hospitalized With Acute Lung Injury Due to COVID-19
- Theravance Biopharma to Participate in Upcoming Investor Conferences
Key People/Management at Theravance Biopharma
Rick Winningham
Chairman, Chief Executive Officer
Gary Barrera
Vice President
Eran Broshy
Director
Dennis O. Driver
Senior Vice President, Human Resources, Organizational and Leadership Development
Reigin Zawadzki
Vice President, Human Resources
Robert V. Gunderson
Director
Theravance Biopharma Office Locations
Theravance Biopharma has offices in Dublin and San Francisco
Dublin, IE (HQ)
Connaught House, 1 Burlington Rd
San Francisco, CA, US
901 Gateway Boulevard
Theravance Biopharma Financials and Metrics
Theravance Biopharma Revenue
Theravance Biopharma's revenue was reported to be $60.37 m in FY, 2018 which is a 292.4% increase from the previous period.
| USD | |
|---|---|
Revenue (FY, 2018) | 60.4m |
Revenue growth (FY, 2017 - FY, 2018), % | 292.4% |
Gross profit (FY, 2018) | 59.7m |
Gross profit margin (FY, 2018), % | 98.8% |
Net income (FY, 2018) | (215.5m) |
EBIT (FY, 2018) | (238.8m) |
Market capitalization (6-Sept-2021) | 622.3m |
Closing stock price (6-Sept-2021) | 8.5 |
Cash (31-Dec-2018) | 378.0m |
EV | 469.1m |
Theravance Biopharma's current market capitalization is $622.3 m.
Annual
Annual
| USD | FY, 2016 | FY, 2017 | FY, 2018 |
|---|---|---|---|
Cash | 344.7m | 89.0m | 378.0m |
Accounts Receivable | 646.0k | 2.3m | 620.0k |
Inventories | 12.2m | 16.8m | |
Current Assets | 528.5m | 378.7m | 532.8m |
Quarterly
| USD | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|
Cash | 128.8m | 148.4m | 86.6m | 169.9m | 139.6m | 91.3m | 125.8m | 103.9m | 101.2m |
Accounts Receivable | 1.5m | 1.9m | 873.0k | 1.2m | 1.3m | 1.6m | 2.0m | 3.4m | 3.0m |
Inventories | 9.4m | 9.8m | 12.5m | 13.2m | 12.1m | 15.3m | 17.2m | 17.9m | 17.9m |
Current Assets | 238.8m | 303.1m | 274.0m | 421.5m | 384.9m | 367.1m | 446.8m | 386.7m | 332.6m |
Annual
| USD | FY, 2016 | FY, 2017 | FY, 2018 |
|---|---|---|---|
Net Income | (190.7m) | (285.4m) | (215.5m) |
Depreciation and Amortization | 3.1m | 4.0m | 3.2m |
Inventories | (3.2m) | (7.3m) | (1.6m) |
Accounts Payable | (16.4m) | 3.8m | 3.6m |
Quarterly
| USD | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | (42.1m) | (89.4m) | (123.3m) | (65.3m) | (131.6m) | (198.5m) | (65.1m) | (105.9m) | (165.3m) |
Depreciation and Amortization | 699.0k | 1.2m | 1.9m | 1.1m | 2.1m | 3.0m | 900.0k | 1.7m | 2.3m |
Inventories | 134.0k | 157.0k | (1.8m) | 140.0k | (497.0k) | (3.0m) | (371.0k) | (351.0k) | (552.0k) |
Accounts Payable | (9.4m) | (10.8m) | (12.8m) | 2.0m | 4.8m | 3.5m | (449.0k) | (2.3m) | (1.7m) |
| USD | Q1, 2016 |
|---|---|
Financial Leverage | 1.2 x |
Theravance Biopharma Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Theravance Biopharma Antibiotics IP | ||
| Theravance Biopharma Ireland Limited | ||
| Theravance Biopharma R&D | ||
| Theravance Biopharma R&D IP | ||
| Theravance Biopharma UK Limited | ||
| Theravance Biopharma US | ||
| Triple Royalty Sub LLC |
Theravance Biopharma Revenue Breakdown
Theravance Biopharma revenue breakdown by geographic segment: 18.4% from Europe, 81.6% from US and 0.0% from Other
Theravance Biopharma Cybersecurity Score
Theravance Biopharma Online and Social Media Presence
Theravance Biopharma's Trends
Theravance Biopharma Company Culture
Overall Culture
B+
75/100
CEO Rating
A+
80/100
Compensation
D
54/100
Theravance Biopharma News and Updates
July 20, 2021
Theravance Biopharma to Report Second Quarter 2021 Financial Results on August 3, 2021
DUBLIN, Ireland, July 20, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will report its second quarter 2021 financial results and...
June 25, 2021
Theravance Biopharma, Inc. Announces Pricing of Public Offering of Ordinary Shares
DUBLIN, June 24, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, announced today the pricing of its...
June 21, 2021
Theravance Biopharma, Inc. Announces Top-Line Results From Phase 2 Study of Nezulcitinib In Patients Hospitalized With Acute Lung Injury Due to COVID-19
DUBLIN and SOUTH SAN FRANCISCO, Calif., June 21, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development, and commercialization of organ-selective...
February 10, 2021
Theravance Biopharma to Participate in Upcoming Investor Conferences
DUBLIN, Feb. 10, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will participate in investor events as follows: Management will be...
November 05, 2020
Theravance Biopharma, Inc. Reports Third Quarter 2020 Financial Results and Provides Business Update
DUBLIN, Nov. 5, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the third quarter ending September 30, 2020. Theravance Biopharma's Total Revenue for the third quarter 2020 was $18.3 million....
July 27, 2020
Theravance Biopharma to Report Second Quarter 2020 Financial Results on August 6, 2020
DUBLIN, July 27, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will report its second quarter 2020 financial results and provide a...
Theravance Biopharma Blogs
September 15, 2021
Theravance Biopharma, Inc. Announces Strategic Actions to Focus on Respiratory Disease Portfolio
Theravance Biopharma, Inc. Announces Strategic Actions to Focus on Respiratory Disease Portfolio
jo-en.bautista…
Wed, 09/15/2021 - 06:06
Theravance Biopharma, Inc. Announces Strategic Actions to Focus on Respiratory Disease Portfolio
September 15, 2021 at 6:06 AM EDT
…
September 15, 2021
Theravance Biopharma, Inc. Announces Top-line Results from a Phase 3 Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension
Theravance Biopharma, Inc. Announces Top-line Results from a Phase 3 Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension
Content Import
Wed, 09/15/2021 - 06:05
Theravance Biopharma, Inc. Announces Top-line Results from a Phase 3 Study of Ampreloxetine in …
August 23, 2021
Theravance Biopharma, Inc. Announces Top-line Results from Phase 2b Dose-Finding Induction Study of Izencitinib in Patients with Ulcerative Colitis
- Randomized, double-blind, placebo-controlled study did not meet the primary endpoint: change in the total Mayo score at week eight, relative to placebo - Izencitinib was well-tolerated and safety data were consistent with expectations for this gut-selective pan-JAK inhibitor - Investor conference
August 03, 2021
Theravance Biopharma, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update
Theravance Biopharma, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update
san.mai@intrado.com
Tue, 08/03/2021 - 16:01
Theravance Biopharma, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update
August 3, 2021 at 4:00 PM E…
June 24, 2021
Theravance Biopharma, Inc. Announces Proposed Public Offering of Ordinary Shares
Theravance Biopharma, Inc. Announces Proposed Public Offering of Ordinary Shares
Content Import
Thu, 06/24/2021 - 16:34
Theravance Biopharma, Inc. Announces Proposed Public Offering of Ordinary Shares
June 24, 2021 at 4:33 PM EDT
This release is a backfill fro…
May 04, 2021
Theravance Biopharma, Inc. Reports First Quarter 2021 Financial Results and Provides Business Update
Theravance Biopharma, Inc. Reports First Quarter 2021 Financial Results and Provides Business Update
san.mai@intrado.com
Tue, 05/04/2021 - 16:09
Theravance Biopharma, Inc. Reports First Quarter 2021 Financial Results and Provides Business Update
May 4, 2021 at 4:05 PM EDT
…
Theravance Biopharma Frequently Asked Questions
When was Theravance Biopharma founded?
Theravance Biopharma was founded in 1996.
Who are Theravance Biopharma key executives?
Theravance Biopharma's key executives are Rick Winningham, Gary Barrera and Eran Broshy.
How many employees does Theravance Biopharma have?
Theravance Biopharma has 363 employees.
What is Theravance Biopharma revenue?
Latest Theravance Biopharma annual revenue is $60.4 m.
What is Theravance Biopharma revenue per employee?
Latest Theravance Biopharma revenue per employee is $166.3 k.
Who are Theravance Biopharma competitors?
Competitors of Theravance Biopharma include Acceleron Pharma, Inflazome and Prothena.
Where is Theravance Biopharma headquarters?
Theravance Biopharma headquarters is located at Connaught House, 1 Burlington Rd, Dublin.
Where are Theravance Biopharma offices?
Theravance Biopharma has offices in Dublin and San Francisco.
How many offices does Theravance Biopharma have?
Theravance Biopharma has 2 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies